NEW YORK (GenomeWeb) – Thermo Fisher Scientific brand One Lambda said today that it has signed an exclusive licensing agreement with Transcriptome Sciences for its transplant rejection testing technology, the Molecular Microscope Diagnostic System (MMDx).

MMDx is a central diagnostic system that uses Thermo Fisher's MyGeneChip custom microarrays to measure transcript levels in biopsy samples, and then apply algorithms that compare those expression results to a set of reference biopsies for diagnosing organ transplant rejection. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.